Related Experiment Video
Updated: Mar 7, 2026
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
[Current biomarkers for gastric cancer]
1Institut für Pathologie, Universitätsklinikum "Carl Gustav Carus", TU Dresden, Fetscherstr.74, 01307, Dresden, Deutschland. gustavo.baretton@uniklinikum-dresden.de.
Abstract:
Gastric cancer is still a relevant malignant disease with high morbidity and mortality. Current molecular genetic data show that gastric cancer, as other solid tumors as well, is not a single entity but consists of several molecular subtypes of gastric cancer with diverse biology. The increasing understanding of molecular pathways is the basis for innovative therapies. These either directly target altered signaling pathways or genes in tumor cells or as in immune checkpoint inhibitors, indirectly target tumor cells by blocking tumor-induced immune inhibition leading to improvement in the prognosis. The selection of eligible patients is a prerequisite for the successful clinical application of these targeted drugs. Pathologists play an important role in integrating tissue-based biomarkers and established pathological parameters (typing, grading and staging) into one comprehensive morphomolecular report.
Insights
Gastric cancer is a complex disease with diverse molecular subtypes. Understanding these subtypes drives innovative therapies and improves patient selection for targeted treatments, enhancing prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastric cancer remains a significant health concern with high morbidity and mortality rates.
- Emerging molecular data reveal gastric cancer is not a singular disease but comprises distinct molecular subtypes with varied biological characteristics.
- Advances in understanding molecular pathways are crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To highlight the importance of molecular subtypes in gastric cancer.
- To emphasize the role of innovative therapies targeting molecular pathways and immune responses.
- To underscore the necessity of precise patient selection for targeted drug efficacy.
Main Methods:
- Analysis of current molecular genetic data for gastric cancer.
- Review of innovative therapeutic approaches, including targeted signaling pathway inhibitors and immune checkpoint inhibitors.
- Emphasis on the integration of pathological parameters and tissue-based biomarkers.
Main Results:
- Gastric cancer exhibits diverse molecular subtypes, influencing its biology.
- Targeted therapies and immune checkpoint inhibitors offer new treatment avenues.
- Patient selection based on molecular and pathological profiles is critical for treatment success.
Conclusions:
- Understanding gastric cancer's molecular heterogeneity is key to advancing treatment.
- Innovative therapies hold promise for improving patient outcomes.
- Pathologists are essential in creating comprehensive morphomolecular reports for informed clinical decisions.
More Related Videos
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Related Concept Videos
01:30Serum Laboratory Studies, Stool Test, Breath Test
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.